384 related articles for article (PubMed ID: 32114479)
1. i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol.
Hyatt A; Gough K; Murnane A; Au-Yeung G; Dawson T; Pearson E; Dhillon H; Sandhu S; Williams N; Paton E; Billett A; Traill A; Andersen H; Beedle V; Milne D
BMJ Open; 2020 Feb; 10(2):e036059. PubMed ID: 32114479
[TBL] [Abstract][Full Text] [Related]
2. Telehealth cancer-related fatigue clinic model for cancer survivors: a pilot randomised controlled trial protocol (the T-CRF trial).
Ladwa R; Pinkham EP; Teleni L; Hanley B; Lock G; Nixon J; Agbejule OA; Crawford-Williams F; Jones L; Pinkham MB; Turner J; Yates P; McPhail SM; Aitken JF; Escalante CP; Hart NH; Chan RJ
BMJ Open; 2022 May; 12(5):e059952. PubMed ID: 35577469
[TBL] [Abstract][Full Text] [Related]
3. A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability.
Lacey J; Lomax AJ; McNeil C; Marthick M; Levy D; Kao S; Nielsen T; Dhillon HM
Support Care Cancer; 2019 Apr; 27(4):1497-1507. PubMed ID: 30392112
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and acceptability of PrE-operative Physical Activity to improve patient outcomes After major cancer surgery: study protocol for a pilot randomised controlled trial (PEPA Trial).
Steffens D; Young J; Beckenkamp PR; Ratcliffe J; Rubie F; Ansari N; Pillinger N; Solomon M
Trials; 2018 Feb; 19(1):112. PubMed ID: 29452599
[TBL] [Abstract][Full Text] [Related]
5. Community-based Rehabilitation Training after stroke: protocol of a pilot randomised controlled trial (ReTrain).
Dean SG; Poltawski L; Forster A; Taylor RS; Spencer A; James M; Allison R; Stevens S; Norris M; Shepherd AI; Calitri R
BMJ Open; 2016 Oct; 6(10):e012375. PubMed ID: 27697876
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
8. Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.
Read T; Webber S; Thomas J; Wagels M; Schaider H; Soyer HP; Smithers BM
BMJ Open; 2017 Oct; 7(10):e016816. PubMed ID: 28988173
[TBL] [Abstract][Full Text] [Related]
9. Personalised Exercise-Rehabilitation FOR people with Multiple long-term conditions (PERFORM): protocol for a randomised feasibility trial.
Simpson SA; Evans RA; Gilbert HR; Branson A; Barber S; McIntosh E; Ahmed Z; Dean SG; Doherty PJ; Gardiner N; Greaves C; Daw P; Ibbotson T; Jani B; Jolly K; Mair F; Ormandy P; Smith S; Singh SJ; Taylor R
BMJ Open; 2024 Apr; 14(4):e083255. PubMed ID: 38580370
[TBL] [Abstract][Full Text] [Related]
10. Web-based cognitive rehabilitation intervention for cancer-related cognitive impairment following chemotherapy for aggressive lymphoma: protocol for a randomised pilot trial.
Gates P; Green HJ; Gough K; Dhillon H; Vardy JL; Dickinson M; Guarnera J; Krishnasamy M; Livingston PM; White V; Ugalde A; Caeyenberghs K
BMJ Open; 2024 Apr; 14(4):e081084. PubMed ID: 38653511
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Managing Cancer and Living Meaningfully (CALM) in people with advanced non-small cell lung cancer treated with immunotherapies or targeted therapies: protocol for a single-arm, mixed-methods pilot study.
Lynch FA; Rodin G; Jefford M; Duffy M; Lai-Kwon J; Heynemann S; Mileshkin L; Briggs L; Burke J; Leigh L; Spelman T; Ftanou M
BMJ Open; 2023 Jul; 13(7):e072322. PubMed ID: 37524546
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
13. Study protocol of the TIRED study: a randomised controlled trial comparing either graded exercise therapy for severe fatigue or cognitive behaviour therapy with usual care in patients with incurable cancer.
Poort H; Verhagen CA; Peters ME; Goedendorp MM; Donders AR; Hopman MT; Nijhuis-van der Sanden MW; Berends T; Bleijenberg G; Knoop H
BMC Cancer; 2017 Jan; 17(1):81. PubMed ID: 28129746
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and preliminary effectiveness of virtual reality as a patient education tool for people with cancer undergoing immunotherapy: a protocol for a randomised controlled pilot study in a regional setting.
van der Kruk SR; Gunn KM; MacDougall H; Milne D; Smith K; Zielinski R
BMJ Open; 2023 Jun; 13(6):e071080. PubMed ID: 37311632
[TBL] [Abstract][Full Text] [Related]
15. Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacy.
Hart NH; Newton RU; Spry NA; Taaffe DR; Chambers SK; Feeney KT; Joseph DJ; Redfern AD; Ferguson T; Galvão DA
BMJ Open; 2017 May; 7(5):e014458. PubMed ID: 28559456
[TBL] [Abstract][Full Text] [Related]
16. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
18. CanWalk: a feasibility study with embedded randomised controlled trial pilot of a walking intervention for people with recurrent or metastatic cancer.
Tsianakas V; Harris J; Ream E; Van Hemelrijck M; Purushotham A; Mucci L; Green JS; Fewster J; Armes J
BMJ Open; 2017 Feb; 7(2):e013719. PubMed ID: 28202500
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
20. eHealth intervention to manage symptoms for patients with cancer on immunotherapy (SOFIA): a study protocol for a randomised controlled external pilot trial.
Sauer C; Krauß J; Jäger D; Zschäbitz S; Haag GM; Walle T; Sauer S; Kiermeier S; Friederich HC; Maatouk I
BMJ Open; 2021 Jul; 11(7):e047277. PubMed ID: 34281921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
